CONVERTING DIPLOIDY TO HAPLOIDY FOR GENETIC DIAGNOSIS
    22.
    发明公开
    CONVERTING DIPLOIDY TO HAPLOIDY FOR GENETIC DIAGNOSIS 有权
    Diploidie的折算HAPLODIE的遗传诊断

    公开(公告)号:EP1220952A2

    公开(公告)日:2002-07-10

    申请号:EP00968746.8

    申请日:2000-10-06

    IPC分类号: C12Q1/68 C12N15/06 C12N5/26

    摘要: Detection of mutations associated with hereditary diseases is complicated by the diploid nature of mammalian cells. Mutations present in one allele are often masked by the wild-type sequence of the other allele. Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion. Nucleic acids from the hybrids can be analyzed for mutations in an unambiguous manner. This approach was used to detect two cancer-causing mutations that had previously defied genetic diagnosis. One of the families studied, Warthin Family G, was the first kindred with a hereditary colon cancer syndrome described in the biomedical literature.

    SAFE SEQUENCING SYSTEM
    25.
    发明公开

    公开(公告)号:EP3907299A1

    公开(公告)日:2021-11-10

    申请号:EP21173115.3

    申请日:2012-04-12

    摘要: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called "Safe-SeqS" for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant ("super-mutants") if =95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.

    SOMATIC MUTATIONS IN ATRX IN BRAIN CANCER
    30.
    发明授权
    SOMATIC MUTATIONS IN ATRX IN BRAIN CANCER 有权
    ATRX在脑癌中的体细胞突变

    公开(公告)号:EP2726869B1

    公开(公告)日:2017-08-09

    申请号:EP12804757.8

    申请日:2012-06-28

    摘要: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.

    摘要翻译: 我们在来自不同地点的447种癌症中确定了ATRX和DAXX的序列。 我们发现小儿胶质母细胞瘤多形性(GBM)(11.1%),成人GBM(6.5%),少突胶质细胞瘤(7.7%)和成神经管细胞瘤(1.5%)中最常见突变; 并表明端粒替代延长(ALT)是一种端粒酶非依赖性端粒维持机制,在未激活端粒酶的癌症中发现,与任一基因的体细胞突变完全相关。 相反,神经母细胞瘤和卵巢癌,乳腺癌和胰腺腺癌的ATRX和DAXX突变均为阴性。 ATRX或DAXX的改变定义了与人类癌症中替代的端粒维持功能密切相关的特定分子途径。